InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026. InnoCare delivered robust revenue…

ONLY AVAILABLE IN PAID PLANS

More from Technology